WO2019059550A2 - COMPOSITION FOR PREVENTING OR TREATING OBESITY, COMPRISING SUPPLEMENT FOR REDUCING BODY FAT AND β-GLUCAN AS ACTIVE INGREDIENTS - Google Patents

Abstract

The present invention relates to a composition for preventing or treating obesity, comprising a supplement for reducing body fat and a β-glucan as active ingredients.

Description

A composition for preventing or treating obesity comprising an active ingredient of a body fat reducing agent and beta-glucan

The present invention relates to a composition for preventing or treating obesity comprising, as an active ingredient, a body fat reducing adjuvant and beta-glucan (in particular beta-glucan derived from skim mushroom).

Obesity is a condition in which excess body fat is increased and metabolic abnormalities are caused. Obesity is considered to be a major risk factor for various adult diseases such as hypertension, diabetes and cardiovascular disease and cancer. As in other countries, the prevalence of obesity in Korean adults has steadily increased over the last 20 years. For years, the World Health Organization (WHO) has become a '21st Century New Infection' and the American Medical Association has defined obesity as a 'disease'. This global movement suggests that obesity is not simply a matter of beauty or physical phenomenon, but a disease that requires treatment. In recent years, Korea has been making efforts to solve obesity by carrying out the government 's obesity campaign along with efforts in the medical and pharmaceutical sectors. Like the medical advanced countries, Korean people are also making awareness of raising awareness of obesity and defining obesity as a disease. Obesity has been associated with type 2 diabetes, cardiovascular disease, osteoarthritis, some cancers, sleep apnea, asthma and nonalcoholic fatty ducts. The purpose of anti-obesity drug therapy is not only weight loss, but also improvement of associated diseases such as hyperglycemia, dyslipidemia, arteriosclerotic heart disease and the like associated with obesity.

 Currently, there is chemotherapy (dietary supplement) as a treatment for obesity. In 2006, a survey conducted by a consumer group found that more than half of Seoul's citizens are taking health supplements, which is why it is easier to come up with something to eat than to maintain a healthy lifestyle "He said. Obesity is also more difficult to eat diet supplements and physical activity, eating health supplements that seem to work better than regular exercise. Therefore, diet supplements are essential for modern obesity treatment. Commonly found dietary supplements include components such as Garcinia cambogia extract (HCA), conjugated linoleic acid (CLA) and dietary fiber. Although there is a difference in supplementation, it has been found that it is effective for suppressing appetite, inhibiting fat accumulation, generating heat and decreasing body fat. However, the fact that the data of this effect is insufficient and the results of side effects are also reported is the biggest problem of chemotherapy . Conjugated Linoleic Acid, or CLA, is abbreviated as Conjugated Linoleic Acid. It was first marketed as a diet food in the United States in 1998. In Korea, in June 2006, HK Biotech was first approved by the Korea Food & Drug Administration After that, some companies are receiving additional approval, and the frequency of handling them in TV home shopping is increasing. Conjugated linoleic acid has been shown to prevent weight gain in animal studies and to inhibit fat accumulation, but side effects have been insulin resistance and fatty liver. It recognizes the increase of insulin in the liver and stops the production of glucose to induce the degradation of glucose. When the insulin resistance increases, this kind of action does not appear and causes type 2 diabetes. In clinical trials, weight loss and body fat reduction after abdominal obesity ingested conjugated linoleic acid also increased insulin resistance and reduced side effects such as hyperglycemia and HDL-cholesterol. Recent studies have shown that acute hepatitis can be induced, and conjugated linoleic acid has liver toxicity that damages the liver.

Therefore, conjugated linoleic acid, which is currently used worldwide as an adjuvant to decrease body fat mass, proves the effect on reducing body fat, but the side effects that cause hepatotoxicity are not solved. Recently, with the increase of obesity population, interest in dieting has increased, and various dietary foods have been developed. As the diet related market is growing greatly, it is very urgent to solve the side effects of diet products.

Beta-glucan is a polysaccharide polymerized mainly by β-1,3 chemical bonds of glucose. It is a microorganism-derived β-glucan (β-1,3-glucan produced by separating from cell wall or cell polysaccharide of mushroom, Or β-1,3-1,6-glucan) and vegetable beta-glucan (β-1,3-1,4-glucan) extracted from cereal fiber such as barley and oats. They may exhibit various physiological activities depending on the more specific glucose bond structure, and they are also used in a variety of high-value biological materials such as cosmetics additives, health supplements, food additives, concrete admixtures and feed additives.

 Beta-glucan (β-Glucan) in the form of β- (1,6) -blocked (1,3) -glucan, known to exist in schizophyllan of Schizophyllum commune, And at the same time, it has been reported that natural immune modulators lacking resistance and physiological activities against anticancer and antioxidation. Beta Glucan is well-known as a biological response modifier (BRM) that acts on the body's immune system to enhance the body's immune system. In particular, beta glucan activates the macrophage function in the immune system, Has been reported to secrete cytokines such as interferon or interleukin, which are proliferation factors of lymphocytes and white blood cells, to enhance the overall function of the immune system. In addition, the hepatotoxicity of the antitumor agent Taxol glucan inhibited the necrosis process to protect the liver. The water-soluble beta-glucan isolated from Agrobacterium sp ZX09 also inhibited hepatic injury Have been reported. It has been confirmed that it can play a role of liver protection in the risk of liver damage.

The present invention is intended to provide a pharmaceutical composition for preventing or treating obesity, which comprises a body fat reducing adjuvant and beta-glucan as an active ingredient for suppressing adverse effects caused by a body fat reducing adjuvant.

However, the technical problem to be solved by the present invention is not limited to the above-mentioned problems, and other matters not mentioned can be clearly understood by those skilled in the art from the following description.

The present invention provides a pharmaceutical composition for preventing or treating obesity, which comprises a body fat reducing adjuvant and beta-glucan as an active ingredient.

The composition may be one for inhibiting side effects due to the body fat reduction adjuvant.

The side effect may be a side effect due to increased hepatic toxicity or blood cholesterol content.

The body fat reducing adjuvant may be at least one member selected from the group consisting of conjugated linoleic acid, Garcinia cambogia extract, and dietary fiber, and may preferably be conjugated linoleic acid.

The beta-glucan may be isolated from Schizophyllum commune or a culture thereof.

The beta-glucan may have a structure of? - (1,6) -bonded (1,3) -glucan.

The body fat reducing adjuvant and the beta-glucan may be mixed at a ratio of 2: 1 (w / v: w / v) to 100: 1 (w / v: w / v).

In one embodiment of the present invention, there is provided a health functional food for preventing or improving obesity comprising a body fat reducing adjuvant and beta-glucan as an active ingredient.

In another embodiment of the present invention, there is provided a use of a body fat reducing adjuvant and beta-glucan for use in a pharmaceutical composition for preventing or treating obesity.

In another embodiment of the present invention, there is provided a use of a body fat reducing adjuvant and beta-glucan for use in a health functional food for preventing or improving obesity.

In another embodiment of the present invention, there is provided a method for treating obesity comprising administering to a subject a body fat reducing adjuvant and beta-glucan.

The present invention relates to a composition for preventing or treating obesity comprising a body fat reducing adjuvant and beta-glucan as an active ingredient, and the composition not only has a synergistic effect of the body fat reducing adjuvant, Which has an advantage of suppressing an increase in blood cholesterol content while suppressing the adverse effect, i.e., liver toxicity.

Therefore, the composition according to the present invention is expected to be useful for the prevention or treatment of obesity, because it is possible to reduce body fat safely to a living body.

FIG. 1 is a photograph of mice after 28 weeks from the start of administration of the drug in Experimental Groups 1-1 to 1-2 and Comparative Experimental Groups 1-1 to 1-3.

FIG. 2 is a graph comparing the results of weekly weighing for 28 weeks after starting administration of the drug in the experimental groups 1-1 to 1-2 and the comparative experimental groups 1-1 to 1-3.

FIG. 3 is a table comparing the results of weighing and tissue weighing after sacrificing mice after 28 weeks of starting dosing drug in experimental groups 1-1 to 1-2 and comparative experimental groups 1-1 to 1-3 .

FIG. 4 is a table comparing the results of serum analysis after sacrifice of mice after 28 weeks of starting administration of the drug in the experimental groups 1-1 to 1-2 and the comparative experimental groups 1-1 to 1-3.

FIG. 5 is a graph comparing the results of weekly weighing for 20 weeks after starting administration of the drug in the experimental groups 2-1 to 2-2 and the comparative experimental groups 2-1 to 2-3.

FIG. 6 is a table comparing the results of weighing and tissue weighing after sacrificing mice 20 weeks after starting administration of the drug in the experimental groups 2-1 to 2-2 and comparative experimental groups 2-1 to 2-3 .

FIG. 7 is a table comparing the results of performing serum analysis after sacrificing mice 20 weeks after starting administration of the drug in the experimental groups 2-1 to 2-2 and the comparative experimental groups 2-1 to 2-3.

The inventors of the present invention have made efforts to overcome side effects of the body fat reducing adjuvant. As a result, when the beta-glucan derived from skim mushroom is administered concurrently, not only the body fat decreasing effect is enhanced but the hepatic toxicity And suppressing the increase of the cholesterol content in the blood while suppressing the increase in blood cholesterol level. On the other hand, when beta-glucan derived from skim mushroom alone is administered alone, it is confirmed that it does not have a significant weight reduction effect.

Hereinafter, the present invention will be described in detail.

Pharmaceutical composition for preventing or treating obesity

The present invention provides a pharmaceutical composition for preventing or treating obesity, which comprises a body fat reducing adjuvant and beta-glucan as an active ingredient.

The pharmaceutical composition for preventing or treating obesity according to the present invention is characterized by containing a body fat reducing adjuvant and beta-glucan as an active ingredient.

The composition is intended for the prevention or treatment of obesity, which can be identified through weight and tissue weighing, or by analysis of triglyceride content and free fatty acid content.

In addition, the composition may be for suppressing side effects due to the body fat reduction adjuvant, and specifically, the side effect may be a side effect due to hepatotoxicity or an increase in blood cholesterol content. More specifically, the liver toxicity can be ascertained through liver weight measurement or through GOT / AST levels and gamma-GPT / ALT numerical analysis.

The body fat reduction adjuvant may be at least one member selected from the group consisting of conjugated linoleic acid, Garcinia cambogia extract and dietary fiber, and may preferably be conjugated linoleic acid or Garcinia cambogia extract. When the conjugate linoleic acid or Garcinia cambogia extract is administered alone, it has a weight reduction effect due to reduction of body fat, but side effects that cause adverse effects due to increase of liver toxicity and blood cholesterol content have been problematic.

On the other hand, the beta-glucan is administered in parallel to suppress side effects due to the body fat reducing adjuvant, and it is preferable that the beta-glucan has a structure of? - (1,6) -blocked (1,3) It does not. The beta-glucan may be derived from microbial cells, yeast cells or mushroom mycelium, and more specifically, it may be isolated from Schizophyllum commune or a culture thereof, but is not limited thereto.

In order to separate the beta-glucan from the skim mushroom, it can be obtained from a culture obtained by liquid culture of the skimmed mushroom mycelium. More specifically, it is more preferable to cultivate skim mushroom as described in Korean Patent No. 10-0892355 or Korean Patent Registration No. 10-0909857, and to separate and obtain beta-glucan from the culture thereof. However, It does not.

(W / v: w / v) of the body fat reduction adjuvant and the beta-glucan are mixed when the first solution containing the body fat reduction adjuvant and the second solution containing the beta-glucan are mixed and administered, (W / v: w / v) to 10: 1 (w / v: w / v), and wherein the body fat reduction adjuvant and the beta- v: w / v), but it is not limited thereto. At this time, when the concentration of the body fat reduction adjuvant is too small, the weight reduction effect is insufficient. When the concentration of the beta-glucan is too small, the toxicity of the blood or the total cholesterol content in the blood can not be effectively inhibited.

On the other hand, when the concentration of the beta-glucan is increased by mixing the body fat reducing adjuvant and the beta-glucan in a ratio of 2: 1 (w / v: w / v) to 100: Toxicity and an increase in the total cholesterol content in blood can be more effectively inhibited.

The pharmaceutical composition for preventing or treating obesity according to the present invention may be formulated in the form of oral preparations such as powders, granules, tablets, capsules, suspensions, emulsions, syrups and aerosols, external preparations, suppositories, Excipients or diluents conventionally used in the manufacture of pharmaceutical compositions for formulation and use in the manufacture of pharmaceutical compositions.

The carrier or the excipient or diluent includes lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, Polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, mineral oil, and the like.

In the case of formulation, a diluent or excipient such as a commonly used filler, a weight agent, a binder, a wetting agent, a disintegrant or a surfactant may be used.

The solid preparation for oral administration may be prepared by mixing at least one excipient such as starch, calcium carbonate, sucrose, lactose, gelatin and the like in the body fat reduction adjuvant and the beta-glucan. In addition to simple excipients, lubricants such as magnesium stearate and talc may also be used.

Examples of liquid formulations for oral use include suspensions, solutions, emulsions, syrups and the like. In addition to water and liquid paraffin which are commonly used diluents, various excipients such as wetting agents, sweeteners, fragrances, preservatives and the like may be included .

Formulations for parenteral administration include sterile aqueous solutions, non-aqueous agents, suspensions, emulsions, freeze-dried preparations, and suppositories. Examples of the suspending agent include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like. As a base for suppositories, witepsol, macrogol, tween 61, cacao paper, laurin, glycerol gelatin and the like can be used.

The preferred dosage of the pharmaceutical composition for the prevention or treatment of obesity according to the present invention varies depending on the condition of the patient, the body weight, the degree of disease, the drug form, the administration route and the period, but can be appropriately selected by those skilled in the art. However, in order to obtain the desired effect, it is possible to administer 0.0001 μg / kg to 400 mg / kg of beta glucan per day, more preferably 0.001 to 200 mg / kg per day. The administration may be carried out once a day or divided into several doses. However, the scope of the present invention is not limited by the dosage.

The pharmaceutical composition for preventing or treating obesity according to the present invention can be administered to mammals such as rats, mice, livestock, and humans in various routes. All modes of administration can be administered, for example, by oral, rectal or intravenous, intramuscular, subcutaneous, intra-uterine or intracerebroventricular injections.

Health functional foods for preventing or improving obesity

The present invention also provides a health functional food for preventing or ameliorating obesity containing a body fat reducing adjuvant and beta-glucan as an active ingredient.

The health functional food for preventing or ameliorating obesity according to the present invention contains a body fat reducing adjuvant and beta-glucan as an active ingredient, and the body fat reducing adjuvant and the beta-glucan are as described above.

In the health functional food for preventing or improving obesity according to the present invention, when the body fat reducing adjuvant and the beta-glucan are used as an additive for a health functional food, they can be added as they are or can be used together with other food or food ingredients, It can be used appropriately according to the method. The amount of the active ingredient to be mixed may be suitably determined according to each use purpose such as prevention, health, or treatment.

Formulations of health functional foods may be in the form of powders, granules, pills, tablets, capsules, as well as in the form of ordinary foods or beverages.

There is no particular limitation on the type of the food, and examples of the food to which the above substance can be added include dairy products including meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gums, , Various soups, beverages, tea, drinks, alcoholic beverages, and vitamin complexes, and may include foods in a conventional sense.

Generally, the amount of the body fat reducing adjuvant and the beta-glucan may be 15 parts by weight or less, preferably 10 parts by weight or less, based on 100 parts by weight of the raw material. However, in the case of long-term consumption intended for health or hygiene purposes or for the purpose of controlling health, the amount may be less than the above range. Further, since the present invention uses natural products, there is no problem in terms of safety. Can also be used.

The beverage in the health functional food according to the present invention may contain various flavors or natural carbohydrates as an additional ingredient such as ordinary beverages. The above-mentioned natural carbohydrates may be monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, polysaccharides such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol and erythritol. Examples of sweeteners include natural sweeteners such as tau martin and stevia extract, synthetic sweeteners such as saccharin and aspartame, and the like. The ratio of the natural carbohydrate may be about 0.01 to 0.04 g, preferably about 0.02 to 0.03 g per 100 mL of the beverage according to the present invention.

In addition to the above, the health functional food for preventing or improving obesity according to the present invention may contain various nutrients, vitamins, electrolytes, flavors, colorants, pectic acid and salts thereof, alginic acid and its salts, organic acids, protective colloid thickening agents, A preservative, a glycerin, an alcohol, and a carbonating agent used in a carbonated drink. In addition, the composition for improving sleep of the present invention may contain flesh for the production of natural fruit juice, fruit juice drink and vegetable drink. These components may be used independently or in combination. The ratio of such additives is not limited, but is generally selected in the range of 0.01 to 0.1 parts by weight based on 100 parts by weight of the health functional food of the present invention.

Further, the present invention provides a use of a body fat reducing adjuvant and beta-glucan for use in a pharmaceutical composition for preventing or treating obesity.

The present invention also provides a use of a body fat reducing adjuvant and beta-glucan for use in a health functional food for preventing or improving obesity.

The present invention also provides a method of treating obesity comprising administering to a subject a body fat reducing adjuvant and beta-glucan.

As used herein, the term " individual " refers to a subject in need of treatment for a disease, and more specifically refers to a human or non-human primate, mouse, rat, dog, cat, horse, Of mammals.

As described above, the present invention relates to a composition for preventing or treating obesity, which comprises a body fat reducing adjuvant and beta-glucan as an active ingredient. The composition not only has a synergistic effect of the body fat reduction adjuvant, It has an advantage that it is possible to inhibit an increase in blood cholesterol content while suppressing adverse effects due to the body fat reduction adjuvant, i.e., liver toxicity.

Therefore, the composition according to the present invention is expected to be useful for the prevention or treatment of obesity, because it is possible to reduce body fat safely to a living body.

Hereinafter, preferred embodiments of the present invention will be described in order to facilitate understanding of the present invention. However, the following examples are provided only for the purpose of easier understanding of the present invention, and the present invention is not limited by the following examples.

[ Example ]

Example  One: On conjugated linoleic acid (CLA)  Beta Glucan in combination with body fat reduction supplements Synergistic effect  And confirming the effect of inhibiting side effects (animal experiment)

Six - week - old wild type C57BL / 6 mice for body fat monitoring were purchased and cultured for 3 days. Specifically, 6 mice were divided into 5 groups, and as shown in Table 1, conjugated linoleic acid (CLA) (Sigma Aldrich) and betaglucan (β- (1,6) -branched (SPG) (manufacturer: Kyogen Biotech) and PBS (Phosphate buffer solution) were administered orally or singly once daily. Specifically, Experimental group 1-1 was orally administered 0.2 ml of CLA (concentration = 10 mg / ml), and after 30 minutes, beta-glucan (β- (1,6) -branched (1,3) - SPG with glucan structure) (concentration = 0.4 mg / ml) was orally administered in 0.2 ml. In the experimental group 1-2, 0.2 ml of CLA (concentration = 10 mg / ml) was orally administered. After 30 minutes, beta-glucan (β- (1,6) -branched (1,3) (SPG) (concentration = 2 mg / ml) was orally administered in 0.2 ml. In the comparative test group 1-1, 0.2 ml of CLA (concentration = 10 mg / ml) was orally administered. In comparison test group 1-2, oral administration of 0.2 ml of betaglucan (β- (1,6) -branched (1,3) -glucan structure-derived SPG) (concentration = 2 mg / ml) And 0.2 ml of PBS (phosphate buffer solution) was orally administered to the comparative test groups 1-3.

	Administered drug concentration	Dose	Number of doses per week	Total duration of treatment
Experiment 1-1	CLA 10 mg / ml + SPG 0.4 mg / ml	Each 0.2 ml	5 times	28 weeks
Experimental group 1-2	CLA 10 mg / ml + SPG 2 mg / ml	Each 0.2 ml	5 times	28 weeks
Comparative Experiment 1-1	CLA 10 mg / ml	0.2 ml	5 times	28 weeks
Comparative Experiment 1-2	SPG 2 mg / ml	0.2 ml	5 times	28 weeks
Comparative Experiment 1-3	PBS	0.2 ml	5 times	28 weeks

The final results of the experimental animals after 28 weeks for each treatment group are shown in FIG. At this time, it was confirmed whether or not the synergistic effect and the side effect inhibiting effect of the body fat reducing adjuvant were shown by the oral administration of the conjugated linoleic acid and the beta glucan in combination with the body fat reducing adjuvant in the animal model in which the body fat amount was increased.

 Specifically, after administration of the drug was started in the experimental groups 1-1 to 1-2 and the comparative experimental groups 1-1 to 1-3, the body weight was measured every week for 28 weeks, and the results are shown in FIG.

As shown in FIG. 2, in the comparative test group 1-1, the weight of the comparative test group 1 was significantly decreased as compared with the comparative test group 1 as the administration time of the drug was elapsed. In the comparative test group 1-2, It is confirmed that there is almost no change in weight compared to the comparative experiment group 1-3. On the other hand, in the case of the test groups 1-1 to 1-2 in which CLA and SPG were co-administered, the weight of the test group 1-1 was further reduced as compared with the comparative test group 1-1 in which CLA alone was administered as the administration time of the drug was elapsed. That is, a synergistic effect of the body fat reduction adjuvant (CLA) was confirmed. In particular, in the experimental group 1-2, it was confirmed that the weight of the experimental group 1-1 was greatly reduced as the administration period of the drug was elapsed.

In addition, mice were sacrificed 28 weeks after starting administration of the drug in the experimental groups 1-1 to 1-2 and the comparative experimental groups 1-1 to 1-3, and then the body weight and tissue weight were measured. The results are shown in FIG. 3 Respectively.

As shown in FIG. 3, in the case of the experimental groups 1-1 to 1-2 and the comparative experimental group 1-1 in which the conjugated linoleic acid, which is a body fat reducing adjuvant, was orally administered, the tissue weights of the body weight and the organs were greatly reduced . However, in the comparative experimental group 1-1, it was confirmed that the weight of the liver tissue was rather increased. In other words, it seems that conjugated linoleic acid, a body fat reducing adjuvant, is a side effect of hepatotoxicity. In the comparative test group 1-2, the weight of the comparative test group 1 to 3 and the tissue weight of each period were almost unchanged.

On the other hand, in the experimental groups 1-1 to 1-2, it was confirmed that the weight of the liver tissue was reduced rather than the weight of the comparative experimental group 1-1. In addition, the tissue weights of spleen, kidney, heart, and muscle are not significantly different.

In addition, mice were sacrificed 28 weeks after starting administration of the drug in the experimental groups 1-1 to 1-2 and the comparative experimental groups 1-1 to 1-3, and serum analysis was performed. The results are shown in FIG. 4 .

As shown in FIG. 4, in the case of the experimental groups 1-1 to 1-2 and the comparative test group 1-1 in which the conjugated linoleic acid as the body fat reducing adjuvant was orally administered, surprisingly, the content of triglyceride and free fatty acid Respectively. However, in the comparison test group 1-1, the total cholesterol level in the blood was increased and the liver damage was found to be compared with the comparative test group 1-3. This suggests that conjugated linoleic acid, which is a body fat reducing adjuvant, increases blood total cholesterol content and causes side effects due to hepatotoxicity (for example, liver weight gain), as already described in Fig.

On the other hand, in the case of the test groups 1-1 to 1-2 in which SPG was administered in combination, it was confirmed that the liver total toxicity can be minimized while the total cholesterol content of the test group 1-1 or 1-3 is significantly lowered. Particularly, in the experimental groups 1 and 2, the total blood cholesterol level was significantly lower than that in the comparative test group 1-2, and the total blood cholesterol and liver toxicity were further lowered as the content of betaglucan was increased.

Example  2: Garcinia Cambogia  extract( HCA ) In combination with beta-glucan. Synergistic effect  And confirming the effect of inhibiting side effects (animal experiment)

Six - week - old wild type C57BL / 6 mice for body fat monitoring were purchased and cultured for 3 days. Specifically, mice were divided into five groups of 10 mice. As shown in Table 2, as a drug to be administered, Garcinia cambogia extract (HCA) (Sigma Aldrich) and betaglucan (β- Branched (1,3) -glucan) (SPG) (manufactured by Kyuzen Biotech) and PBS (phosphate buffer solution) were orally administered orally once daily. Specifically, in the experimental group 2-1, 0.2 ml of HCA (concentration = 10 mg / ml) was orally administered and after 30 minutes, beta- glucan (β- (1,6) -branched (1,3) - SPG with glucan structure) (concentration = 0.4 mg / ml) was orally administered in 0.2 ml. In the experimental group 2-2, 0.2 ml of HCA (concentration = 10 mg / ml) was orally administered. After 30 minutes, β-glucuronide-derived (β- (1,6) (SPG) (concentration = 2 mg / ml) was orally administered in 0.2 ml. In the comparative experimental group 2-1, 0.2 ml of HCA (concentration = 10 mg / ml) was orally administered. In the comparative experimental group 2-2, 0.2 ml of oral administration of betaglucan (β- (1,6) -branched (1,3) -glucan structure-derived SPG) (concentration = 2 mg / ml) And 0.2 ml of PBS (Phosphate buffer solution) was orally administered to the comparative test groups 2-3.

	Administered drug concentration	Dose	Number of doses per week	Total duration of treatment
Experiment 2-1	HCA 10 mg / ml + SPG 0.4 mg / ml	Each 0.2 ml	5 times	20 weeks
Experiment 2-2	HCA 10 mg / ml + SPG 2 mg / ml	Each 0.2 ml	5 times	20 weeks
Comparative Experiment Group 2-1	HCA 10 mg / ml	0.2 ml	5 times	20 weeks
Comparative Experiment Group 2-2	SPG 2 mg / ml	0.2 ml	5 times	20 weeks
Comparative Experiment 2-3	PBS	0.2 ml	5 times	20 weeks

At this time, it was confirmed whether or not the body fat reducing adjuvant, Garminia cambogia extract and beta glucan, were orally administered in combination in an animal model in which body fat saturation increased, thereby exhibiting the synergistic effect and the side effect inhibiting effect of the body fat reducing adjuvant.

Specifically, after administration of the drug was started in the experimental groups 2-1 to 2-2 and the comparative experimental groups 1-1 to 1-3, the body weight was measured every week for 20 weeks, and the results are shown in FIG.

As shown in FIG. 5, in the comparative experimental group 2-1, the body weight of the comparative experimental group 2-2 was significantly reduced as the administration time of the drug was elapsed, but in the comparative experimental group 2-2, As a result, it is confirmed that there is almost no change in weight compared to the comparative test group 2-3. On the other hand, in the case of the experimental groups 2-1 to 2-2 in which HCA and SPG were co-administered, it was confirmed that the weight of the test group 2-1 was further reduced as compared with the comparative test group 2-1 in which HCA alone was administered as the administration time of the drug was elapsed. That is, the synergistic effect of the body fat reduction adjuvant (HCA) was confirmed. In particular, in the experimental group 2-2, the body weight of the experimental group 2-1 was significantly reduced as the administration time of the drug was elapsed.

In addition, mice were sacrificed 20 weeks after starting administration of the drug in the experimental groups 2-1 to 2-2 and the comparative experimental groups 2-1 to 2-3, and the body weight and tissue weight were measured. The results are shown in FIG. 6 Respectively.

As shown in FIG. 6, in the case of the experimental groups 2-1 to 2-2 and the comparative experimental group 2-1 in which the extract of Garcinia cambogia, which is a body fat reducing adjuvant, was orally administered, the body weight and the tissue weight of each organ were larger Respectively. However, in the comparative experimental group 2-1, the weight of the liver tissue is rather increased. In other words, it seems that the extract of Garcinia cambogia, a body fat reducing adjuvant, is caused by side effects of hepatotoxicity. In comparative experimental group 2-2, it was confirmed that there was little change in body weight and tissue weight in comparison with comparative experimental group 2-3.

On the other hand, in the experimental groups 2-1 to 2-2, it was confirmed that the weight of the liver tissue was reduced rather than the weight of the comparative experimental group 2-1. In addition, the tissue weights of spleen, kidney, heart, and muscle are not significantly different.

In addition, mice were sacrificed 20 weeks after starting administration of the drug in the experimental groups 2-1 to 2-2 and the comparative experimental groups 2-1 to 2-3, and serum analysis was performed. The results are shown in FIG. 7 .

As shown in FIG. 7, in the case of the experimental groups 2-1 to 2-2 and the comparative experimental group 2-1 in which the extract of Garcinia cambogia, which is a body fat reducing adjuvant, was orally administered, surprisingly, the triglyceride and the free fatty acid content were half Or more. ≪ / RTI > However, in the comparative experimental group 2-1, the total cholesterol content in the blood was increased and the liver damage was observed in comparison with the comparative experimental group 2-3. This suggests that the extract of Garcinia cambogia, a body fat reducing adjuvant, increases the total cholesterol content in the blood and causes side effects due to liver toxicity (for example, liver weight increase), as already described in Fig.

On the other hand, in the case of the experimental groups 2-1 to 2-2 in which SPG was administered in combination, it was confirmed that the total cholesterol content in the blood was significantly lowered compared to the comparative test group 1-1 or 1-3, but the liver toxicity was minimized. In particular, in the experimental groups 2-1 to 2-2, the total blood cholesterol level was significantly lower than that of the comparative test group 2-2, and the total blood cholesterol content and liver toxicity were further lowered as the content of beta glucan increased Respectively.

Hereinafter, formulation examples of the composition containing the compound of the present invention will be described, but the present invention is not intended to be limited thereto but is specifically described.

Formulation example  One: Sanje  Produce

400 mg of body fat reducing adjuvant and 20 mg of betaglucan

Lactose hydrate 100 mg

Talc 10 mg

The above ingredients were mixed and filled in an airtight container to prepare powders.

Formulation example  2: Preparation of tablets

100 mg of body fat reducing adjuvant and 20 mg of beta glucan

Corn starch 100 mg

100mg of lactose hydrate

Magnesium stearate 2 mg

After mixing the above components, tablets were prepared by tableting according to a conventional method for producing tablets.

Formulation example  3: Preparation of capsules

100 mg of body fat reducing adjuvant and 20 mg of beta glucan

Microcrystalline cellulose 3 mg

Lactose hydrate 14.8 mg

Magnesium stearate 0.2 mg

After mixing the above components, the capsules were filled in gelatin capsules according to the usual preparation method of capsules.

Formulation example  4: Preparation of injection

50 mg of body fat reducing adjuvant and 10 mg of betaglucan

180 mg mannitol

Sterile sterilized water for injection 2974 mg

Sodium dihydrogenphosphate 26 mg

After the above components were mixed, they were prepared with the above ingredient contents per ampoule (2 mL) according to the usual injection preparation method.

Formulation example  5: Liquid  Produce

100 mg of body fat reducing adjuvant and 10 mg of betaglucan

10 g per isomer

5 g mannitol

Purified water quantity

Lemon incense quantity

The components are dissolved in purified water according to the usual preparation method, and the lemon fragrance is added in an appropriate amount. Then purified water is added to adjust the total volume to 100 mL, sterilized and filled in a brown bottle to prepare a liquid preparation.

Formulation example  6: Manufacture of Health Functional Foods

800 mg of body fat reducing adjuvant and 40 mg of betaglucan

Vitamin mixture quantity

70 [mu] g of vitamin A acetate

Vitamin E 1.0 mg

0.13 mg of vitamin B ₁

0.15 mg of vitamin B ₂

0.5 mg of vitamin B ₆

Vitamin B ₁₂ 0.2 g

10 mg vitamin C

Biotin 10 μg

Nicotinic acid amide 1.7 mg

50 ㎍ of folic acid

Calcium pantothenate 0.5 mg

Mineral mixture quantity

1.75 mg of ferrous sulfate

0.82 mg of zinc oxide

Magnesium carbonate 25.3 mg

15 mg of potassium phosphate monobasic

Secondary calcium phosphate 55 mg

Potassium citrate 90 mg

100 mg of calcium carbonate

24.8 mg of magnesium chloride

Although the composition ratio of the above-mentioned vitamin and mineral mixture is comparatively mixed with a component suitable for a health functional food as a preferred embodiment, the compounding ratio may be arbitrarily modified, and the above components may be mixed And then granules are prepared and used in the manufacture of health functional foods according to conventional methods.

Formulation example  7: Manufacture of health drinks

400 mg of body fat reducing adjuvant and 10 mg of beta-glucan

Vitamin C 15 g

Vitamin E (powder) 100 g

19.75 g of ferrous lactate

3.5 g of zinc oxide

Nicotinic acid amide 3.5 g

Vitamin A 0.2 g

Vitamin B ₁ 0.25 g

Vitamin B ₂ 0.3 g

Purified water quantitation

The above components were mixed according to a conventional health drink manufacturing method, and the mixture was stirred and heated at 85 for about 1 hour. The resulting solution was filtered to obtain a sterilized 2-liter container, which was sealed and sterilized, ≪ / RTI >

Although the compositional ratio is relatively mixed with a component suitable for a favorite drink, it is also possible to arbitrarily modify the compounding ratio according to the regional or national preference such as the demand class, the demanding country, and the use purpose.

It will be understood by those skilled in the art that the foregoing description of the present invention is for illustrative purposes only and that those of ordinary skill in the art can readily understand that various changes and modifications may be made without departing from the spirit or essential characteristics of the present invention. will be. It is therefore to be understood that the above-described embodiments are illustrative and non-restrictive in every respect.

Claims (12)

1. A composition for preventing or treating obesity, which comprises a body fat reducing adjuvant and beta-glucan as an active ingredient.
2. The method according to claim 1,

   Wherein the composition is for inhibiting adverse effects due to a body fat reducing adjuvant.
3. 3. The method of claim 2,

   Wherein said side effect is a side effect due to an increase in liver toxicity or blood total cholesterol content.
4. The method according to claim 1,

   Wherein the body fat reducing adjuvant is at least one selected from the group consisting of conjugated linoleic acid, Garcinia cambogia extract, and dietary fiber.
5. 5. The method of claim 4,

   Wherein the body fat reducing adjuvant is a conjugated linoleic acid or Garcinia cambogia extract.
6. The method according to claim 1,

   Wherein said beta-glucan is isolated from Schizophyllum commune or a culture thereof.
7. The method according to claim 1,

   Wherein the beta-glucan has a structure of? - (1,6) -blocked (1,3) -glucan.
8. The method according to claim 1,

   Wherein the body fat reducing adjuvant and the beta-glucan are mixed at a ratio of 2: 1 (w / v: w / v) to 100: 1 (w / v: w / v) Composition.
9. A health functional food for prevention or improvement of obesity, which comprises a body fat reducing adjuvant and beta-glucan as an active ingredient.
10. Use of a body fat reducing adjuvant and beta-glucan for use in a pharmaceutical composition for preventing or treating obesity.
11. Use of a body fat reducing adjuvant and beta-glucan for use in a health functional food for preventing or improving obesity.
12. A method of treating obesity comprising administering to a subject a body fat reducing adjuvant and beta-glucan.

Images